Triple-combination therapy reduces COPD exacerbations

GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol significantly reduced the amount of exacerbations experienced by patients with chronic obstructive pulmonary disease compared with AstraZeneca’s Symbicort Turbohaler, according to phase 3 study results presented at the 2016 European Respiratory Society International Congress.

Results showed that patients in the triple-combination therapy group had improved lung function and a significantly reduced rate of COPD–related exacerbations. The researchers reported that they observed a 35% and 44% reduction of exacerbations in the FF/UMEC/VI group versus the Symbicort Turbohaler group at 24 and 52 weeks, respectively.

More…

%d bloggers like this: